VKTX - Viking Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development13,741.1869,000.4996,966.84222,223.073
Selling General and Administrative5,329.0034,846.7765,029.6361,244.91
Non Recurring----
Others----
Total Operating Expenses19,070.18913,847.27511,996.47823,467.983
Operating Income or Loss-19,070.189-13,847.275-11,996.478-23,467.983
Income from Continuing Operations
Total Other Income/Expenses Net-1,507.476-884.547-11,407.511,583.8
Earnings Before Interest and Taxes-19,070.189-13,847.275-11,996.478-23,467.983
Interest Expense-1,950.547-2,032.34-1,018.502-628.676
Income Before Tax-20,577.665-14,731.822-23,403.988-21,884.183
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-20,577.665-14,731.822-23,403.988-21,884.183
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-20,577.665-14,731.822-23,403.988-21,884.183
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-20,577.665-14,731.822-23,403.988-21,884.183